Logo image of DXR

DAXOR CORP (DXR) Stock Fundamental Analysis

NASDAQ:DXR - Nasdaq - US2394671034 - Common Stock - Currency: USD

10.68  +0.08 (+0.75%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to DXR. DXR was compared to 187 industry peers in the Health Care Equipment & Supplies industry. While DXR seems to be doing ok healthwise, there are quite some concerns on its profitability. DXR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

DXR had positive earnings in the past year.
DXR had a positive operating cash flow in the past year.
Of the past 5 years DXR 4 years were profitable.
In the past 5 years DXR reported 4 times negative operating cash flow.
DXR Yearly Net Income VS EBIT VS OCF VS FCFDXR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M

1.2 Ratios

DXR has a Return On Assets of 1.46%. This is in the better half of the industry: DXR outperforms 73.80% of its industry peers.
DXR has a better Return On Equity (1.50%) than 72.19% of its industry peers.
Industry RankSector Rank
ROA 1.46%
ROE 1.5%
ROIC N/A
ROA(3y)6.45%
ROA(5y)5.61%
ROE(3y)6.73%
ROE(5y)6.34%
ROIC(3y)N/A
ROIC(5y)N/A
DXR Yearly ROA, ROE, ROICDXR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60

1.3 Margins

DXR's Profit Margin of 447.75% is amongst the best of the industry. DXR outperforms 99.47% of its industry peers.
In the last couple of years the Profit Margin of DXR has declined.
DXR does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 447.75%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-35.84%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DXR Yearly Profit, Operating, Gross MarginsDXR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K 2K

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for DXR has been increased compared to 1 year ago.
DXR has more shares outstanding than it did 5 years ago.
The debt/assets ratio for DXR has been reduced compared to a year ago.
DXR Yearly Shares OutstandingDXR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
DXR Yearly Total Debt VS Total AssetsDXR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

DXR has an Altman-Z score of 38.36. This indicates that DXR is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 38.36, DXR belongs to the top of the industry, outperforming 98.93% of the companies in the same industry.
DXR has a debt to FCF ratio of 28.40. This is a negative value and a sign of low solvency as DXR would need 28.40 years to pay back of all of its debts.
DXR's Debt to FCF ratio of 28.40 is fine compared to the rest of the industry. DXR outperforms 68.98% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that DXR is not too dependend on debt financing.
DXR has a better Debt to Equity ratio (0.02) than 65.78% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 28.4
Altman-Z 38.36
ROIC/WACCN/A
WACCN/A
DXR Yearly LT Debt VS Equity VS FCFDXR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M

2.3 Liquidity

A Current Ratio of 0.02 indicates that DXR may have some problems paying its short term obligations.
DXR has a worse Current ratio (0.02) than 98.93% of its industry peers.
A Quick Ratio of 0.02 indicates that DXR may have some problems paying its short term obligations.
DXR has a worse Quick ratio (0.02) than 98.93% of its industry peers.
Industry RankSector Rank
Current Ratio 0.02
Quick Ratio 0.02
DXR Yearly Current Assets VS Current LiabilitesDXR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M

More info and screens

1

3. Growth

3.1 Past

DXR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 574.51%, which is quite impressive.
DXR shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -54.84% yearly.
Looking at the last year, DXR shows a very negative growth in Revenue. The Revenue has decreased by -26.28% in the last year.
The Revenue for DXR have been decreasing by -20.63% on average. This is quite bad
EPS 1Y (TTM)574.51%
EPS 3Y-54.84%
EPS 5YN/A
EPS Q2Q%-26.11%
Revenue 1Y (TTM)-26.28%
Revenue growth 3Y-24.67%
Revenue growth 5Y-20.63%
Sales Q2Q%-41.82%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DXR Yearly Revenue VS EstimatesDXR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M
DXR Yearly EPS VS EstimatesDXR Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 0.02 0.04 0.06 0.08

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 62.82 indicates a quite expensive valuation of DXR.
DXR's Price/Earnings ratio is a bit cheaper when compared to the industry. DXR is cheaper than 66.84% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.84, DXR is valued quite expensively.
Industry RankSector Rank
PE 62.82
Fwd PE N/A
DXR Price Earnings VS Forward Price EarningsDXR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, DXR is valued a bit cheaper than 64.71% of the companies in the same industry.
Industry RankSector Rank
P/FCF 2061.2
EV/EBITDA N/A
DXR Per share dataDXR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DXR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DAXOR CORP

NASDAQ:DXR (8/18/2025, 12:33:41 PM)

10.68

+0.08 (+0.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-29 2024-02-29/amc
Earnings (Next)N/A N/A
Inst Owners1.96%
Inst Owner Change12.21%
Ins Owners5.44%
Ins Owner Change0.11%
Market Cap52.97M
Analysts80
Price Target25.5 (138.76%)
Short Float %0.51%
Short Ratio2.59
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 62.82
Fwd PE N/A
P/S 442.18
P/FCF 2061.2
P/OCF 2061.2
P/B 1.48
P/tB 1.48
EV/EBITDA N/A
EPS(TTM)0.17
EY1.59%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.01
FCFY0.05%
OCF(TTM)0.01
OCFY0.05%
SpS0.02
BVpS7.22
TBVpS7.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.46%
ROE 1.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 447.75%
GM N/A
FCFM 21.45%
ROA(3y)6.45%
ROA(5y)5.61%
ROE(3y)6.73%
ROE(5y)6.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-35.84%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 28.4
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 4.79%
Current Ratio 0.02
Quick Ratio 0.02
Altman-Z 38.36
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)574.51%
EPS 3Y-54.84%
EPS 5YN/A
EPS Q2Q%-26.11%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-26.28%
Revenue growth 3Y-24.67%
Revenue growth 5Y-20.63%
Sales Q2Q%-41.82%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-75.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y100.7%
FCF growth 3YN/A
FCF growth 5Y-61.68%
OCF growth 1Y100.7%
OCF growth 3YN/A
OCF growth 5Y-61.68%